BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease.
about
Drug-eluting stentsThe pharmacokinetics of Biolimus A9 after elution from the Nobori stent in patients with coronary artery disease: the NOBORI PK study.A review of current devices and a look at new technology: drug-eluting stents.Development and validation of a semi-automated assay for the highly sensitive quantification of Biolimus A9 in human whole blood using high-performance liquid chromatography-tandem mass spectrometry.Histopathological Comparison among Biolimus, Zotarolimus and Everolimus-Eluting Stents in Porcine Coronary Restenosis Model.Current status of the Xience V® everolimus-eluting coronary stent system.Stents as a platform for drug delivery.Drug-eluting metallic stents in urology.Pharmacological inhibition of coronary restenosis: systemic and local approaches.Natural product and natural product derived drugs in clinical trials.Drug-eluting stents to prevent stent thrombosis and restenosis.Surface functionalization of poly(ε-caprolactone) improves its biocompatibility as scaffold material for bioartificial vessel prostheses.In vitro and in vivo characterization of novel biodegradable polymers for application as drug-eluting stent coatings.In vivo comparison of a polymer-free Biolimus A9-eluting stent with a biodegradable polymer-based Biolimus A9 eluting stent and a bare metal stent in balloon denuded and radiated hypercholesterolemic rabbit iliac arteries.In vitro study of dual drug-eluting stents with locally focused sirolimus and atorvastatin release.Effectiveness and Safety of Biolimus A9™-Eluting stEnt in Patients with AcUTe Coronary sYndrome; A Multicenter, Observational Study (BEAUTY Study).The risks and benefits of drug-eluting stents.Procedural and follow-up outcomes among patients undergoing successful recanalisation of coronary chronic total occlusions using biolimus drug-eluting stents.Solely abluminal drug release from coronary stents could possibly improve reendothelializationA rapamycin derivative, biolimus, preferentially activates autophagy in vascular smooth muscle cells
P2860
Q34091036-DAA5B7D0-0F06-4759-A833-E4414EE74215Q37003748-C32441A7-913F-4A81-A5C9-2B4C47538355Q37357342-48228B3D-A8EB-4275-B505-F82922A95CA8Q37394867-C432F421-7CEE-43FD-BC2D-AC8249348D7FQ37399625-86164107-AF52-48E4-9DE8-ACDB667FD81BQ37799356-5B4AF1D3-036B-4934-96F2-1397848AB40CQ37872741-5DE9654B-4748-44A0-B4D5-DF37BCE01B4BQ38185370-F319C546-B7D7-446D-8D31-C5CFBF6B8A87Q38241974-10837BC1-4E37-4152-AD96-FDA1ADCA3F12Q38247457-18481FB4-D38F-4A72-92DC-5A240CA3385AQ38633332-D32B6BB5-BEBC-4509-A243-6B77C6C6E2B5Q39544422-6BD2135C-7CD1-48F4-B25C-5228C8B60639Q43127564-F820CD50-794E-4A39-AB5B-6C1D5CE08DDEQ44067567-5720EEF2-BEF5-4CA2-A352-8BA8EF4E2A22Q46783365-C94AEECD-53B0-4191-BECA-B3A4958D210AQ47157179-11B70675-111A-419A-94D5-27E353E1470AQ50944377-8C59A425-5901-4F82-B072-344239E5CD0CQ53634713-9D4DA5B6-910F-40DB-8358-8484E6A93FAEQ57916573-76DF65AB-68FC-4268-B992-B3DA4372C543Q58589497-922B867A-C2F7-4D80-ADEA-A4A81FBE360A
P2860
BioMatrix Biolimus A9-eluting coronary stent: a next-generation drug-eluting stent for coronary artery disease.
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
BioMatrix Biolimus A9-eluting ...... t for coronary artery disease.
@ast
BioMatrix Biolimus A9-eluting ...... t for coronary artery disease.
@en
type
label
BioMatrix Biolimus A9-eluting ...... t for coronary artery disease.
@ast
BioMatrix Biolimus A9-eluting ...... t for coronary artery disease.
@en
prefLabel
BioMatrix Biolimus A9-eluting ...... t for coronary artery disease.
@ast
BioMatrix Biolimus A9-eluting ...... t for coronary artery disease.
@en
P2860
P356
P1476
BioMatrix Biolimus A9-eluting ...... t for coronary artery disease.
@en
P2093
Eberhard Grube
Lutz Buellesfeld
P2860
P304
P356
10.1586/17434440.3.6.731
P577
2006-11-01T00:00:00Z